Arbutus Biopharma
ABUS
127 hedge funds and large institutions have $89.1M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
56% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $1.25M
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
12% more funds holding
Funds holding: 113 → 127 (+14)
1.29% more ownership
Funds ownership: 29.8% → 31.08% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less capital invested
Capital invested by funds: $120M → $89.1M (-$30.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$5.07M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$2.42M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$925K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$691K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
-$5.19M |
| 2 |
Millennium Management
New York
|
-$1.53M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$533K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$209K |
| 5 |
Goldman Sachs
New York
|
-$189K |
ABUS Hedge Fund Activity: Q3 2022 in Review
127 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2022, worth a combined $89.1M — down 26% from $120M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ABUS positions and 5 closed out — a net gain of 15 holders — while 44 added to existing stakes and 33 trimmed.
The largest buyer was Two Seas Capital, adding an estimated $5.07M. The largest seller was Brookfield Corp, exiting entirely with an estimated $5.19M sold.
- 127 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2022, up from 113 in Q2 2022.
- Funds reported $89.1M of Arbutus Biopharma stock for Q3 2022, down 26% quarter-over-quarter.
- 20 funds opened new Arbutus Biopharma positions in Q3 2022 and 5 closed out, a net change of +15 holders.
- The largest Arbutus Biopharma buyer in Q3 2022 was Two Seas Capital, an estimated $5.07M added.
- The largest Arbutus Biopharma seller in Q3 2022 was Brookfield Corp, an estimated $5.19M sold.
Based on aggregated 13F filings for Q3 2022.